Simris Biologics Signs Agreement with Nuvisan for In-Vivo Evaluation of Novel Microcystin Payloads
5 juni, 09:15
Simris Group AB (Nasdaq First North: SIMRIS) today announced that its wholly owned subsidiary,Simris Biologics GmbH, has entered into an agreement withNuvisan, a leading European contract research and development organization, to conduct an in-vitro and in-vivo study of Simris’ proprietary microcystin (MC) payloads for antibody-drug conjugates (ADCs).
Under the terms of the agreement, Nuvisan will initiate a stage-gated work program to evaluate multiple distinct MC payload variants developed by Simris Biologics. The study will start with lab-based tests (in vitro efficacy) to see how well these compounds work against cancer cells. The most promising candidates will then move on to testing in living models (in vivo tolerability) to assess safety and potential side effects. Additionally, we’ll test how these drug candidates interact with immune cells from human blood to better understand their potential impact.
In a follow-up study, the top-performing candidate will be tested further to evaluate how well the ADC works against cancer in a living system (in vivo efficacy).
The project will leverage a commercially available monoclonal antibody, eliminating the need for de novo antibody generation and enabling rapid advancement.
Key features of the collaboration include:
- Use of a cost-efficient, clinically relevant antibody
- Initial in-vitro efficacy test expected to take about 1.5 months
- In-vivo tolerability studies expected to be completed within 3 months
- Additional testing with human immune cells to support selection of the best drug candidate
The collaboration reflects Simris’ commitment to developing novel, cyanobacteria-derived toxin payloads with improved therapeutic windows and differentiated mechanisms of action.
For more information about Simris Biologics, please visit: https://simrisbiologics.com
For more information about Nuvisan, visit: https://www.nuvisan.com
Contact Details:
Dr Alexis Roberts-McIntosh
CEO Simris Group AB
Email: ir@simris.com
Mobile: +44 (0) 7940 585298
www.simrisgroup.com
About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.
Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.
Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.
Attachments
Simris Biologics Signs Agreement with Nuvisan for In-Vivo Evaluation of Novel Microcystin Payloads
Ämnen i artikeln
Simris Biologics Signs Agreement with Nuvisan for In-Vivo Evaluation of Novel Microcystin Payloads
5 juni, 09:15
Simris Group AB (Nasdaq First North: SIMRIS) today announced that its wholly owned subsidiary,Simris Biologics GmbH, has entered into an agreement withNuvisan, a leading European contract research and development organization, to conduct an in-vitro and in-vivo study of Simris’ proprietary microcystin (MC) payloads for antibody-drug conjugates (ADCs).
Under the terms of the agreement, Nuvisan will initiate a stage-gated work program to evaluate multiple distinct MC payload variants developed by Simris Biologics. The study will start with lab-based tests (in vitro efficacy) to see how well these compounds work against cancer cells. The most promising candidates will then move on to testing in living models (in vivo tolerability) to assess safety and potential side effects. Additionally, we’ll test how these drug candidates interact with immune cells from human blood to better understand their potential impact.
In a follow-up study, the top-performing candidate will be tested further to evaluate how well the ADC works against cancer in a living system (in vivo efficacy).
The project will leverage a commercially available monoclonal antibody, eliminating the need for de novo antibody generation and enabling rapid advancement.
Key features of the collaboration include:
- Use of a cost-efficient, clinically relevant antibody
- Initial in-vitro efficacy test expected to take about 1.5 months
- In-vivo tolerability studies expected to be completed within 3 months
- Additional testing with human immune cells to support selection of the best drug candidate
The collaboration reflects Simris’ commitment to developing novel, cyanobacteria-derived toxin payloads with improved therapeutic windows and differentiated mechanisms of action.
For more information about Simris Biologics, please visit: https://simrisbiologics.com
For more information about Nuvisan, visit: https://www.nuvisan.com
Contact Details:
Dr Alexis Roberts-McIntosh
CEO Simris Group AB
Email: ir@simris.com
Mobile: +44 (0) 7940 585298
www.simrisgroup.com
About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.
Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.
Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.
Attachments
Simris Biologics Signs Agreement with Nuvisan for In-Vivo Evaluation of Novel Microcystin Payloads
Ämnen i artikeln
Börsen idag
-992x558.webp&w=3840&q=75)
Börsen idag
Börsen idag
Mest läst
Börsen idag
Senaste nytt
Marknadsöversikt
OMX Stockholm 30
1 DAG %
−0,67%
Senast
2 512,53
1 mån
Loading market data...
Privatekonomi med Placeras expert
Affärsvärlden
